Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2013

View Archived Issues

Elimination of leukemia stem cells observed for PF-04449913

Novel oncolytic agents with epigenetic targets described

Shire updates accomplishments of fourth quarter 2012

Small molecules targeting RNA improve experimental myotonic dystrophy type 1

Trial of temsirolimus in prostate cancer stopped prematurely

Boehringer Ingelheim divulges new LTA-4 hydrolase inhibitors

Georgia State University patents novel cyanine dyes for cancer

Abbott Laboratories prepares new protein kinase inhibitors

German group discloses novel TRPV1 ligands

Researchers at Allergan disclose novel alpha2-adrenoceptor agonists

CS-6 shows activity against ovarian cancer stem cells

PIQUR Therapeutics secures funding to develop innovative anticancer therapies

Roche and Chiasma enter into a collaboration agreement for Octreolin

FDA grants orphan drug status to SOV's testosterone undecanoate

Idursulfase beta gains orphan drug status in U.S.

FDA grants orphan drug status to diabetes vaccine candidate

Regeneron and Bayer initiate new phase III aflibercept study

FDA accepts lixisenatide NDA for review

Theracrine synthesizes new fascin inhibitors for cancer

Vorsetuzumab mafodotin shows promising activity in patients with CD70-positive RCC

Edison reports initiation of phase II study of EPI-743

New androgen receptor agonists divulged by Novartis

Novel inhibitors of tankyrase synthesized at Novartis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...